Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL17243108

CC1(C)OB(C2=CCCNC2)OC1(C)C.O=C(O)C(F)(F)F

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
F2 P00734 3/20 0.42
F11 P03951 3/20 0.42
PRSS1 P07477 2/20 0.42
PRSS2 P07478 2/20 0.42
PRSS3 P35030 2/20 0.42
P2RX7 Q99572 1/20 0.42
TSHR P16473 1/20 0.37
SLC6A1 P30531 1/20 0.37
SLC6A13 Q9NSD5 1/20 0.37
BLM P54132 1/20 0.36
MAPK1 P28482 1/20 0.34
CHRM3 P20309 1/20 0.34
F10 P00742 1/20 0.33
P4HB P07237 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14529972 0.85 P2RX7 (0.55) P2RX7TSHRSLC6A1SLC6A13BLM
Hydrochloric Acid SCHEMBL25367828 0.84 P2RX7 (0.53) P2RX7TSHRSLC6A1SLC6A13BLM
Trifluoroacetic Acid SCHEMBL4111685 0.78 F2 (0.42) F2F11PRSS1PRSS2PRSS3
Trifluoroacetic Acid SCHEMBL29672463 0.78 F2 (0.42) F2F11PRSS1PRSS2PRSS3
SCHEMBL12791545 0.69 P2RX7 (0.48) P2RX7MAPK1
Trifluoroacetic Acid SCHEMBL6217291 0.69 TSHR (0.58) TSHRSLC6A1SLC6A13BLMCHRM3
Hydrochloric Acid SCHEMBL29043350 0.68 P2RX7 (0.47) P2RX7MAPK1
Trifluoroacetic Acid SCHEMBL20593353 0.67 F2 (0.39) F2F11PRSS1PRSS2PRSS3
Trifluoroacetic Acid SCHEMBL20294675 0.67 F2 (0.53) F2F11PRSS1PRSS2PRSS3
Trifluoroacetic Acid SCHEMBL2543116 0.67 F2 (0.53) F2F11PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109715-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) 2026-04-23 US disclosed
EP-4600246-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE Public University Corporation Yokohama City University (JP) 2025-08-13 EP disclosed
WO-2024075696-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE 公立大学法人横浜市立大学 2024-04-11 WO disclosed
US-9839642-B2 Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-12-12 US disclosed
US-20170173035-A1 BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-06-22 US disclosed
EP-3139918-A1 BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-03-15 EP disclosed
WO-2015171474-A1 BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170173035-A1 BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS MGAM, CMBL, PEPD F2 1168/4885F11 1548/4885PRSS1 703/4885
US-20260109715-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE SMG1, RACK1, TIA1 F2 4527/4885F11 3228/4885PRSS1 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.